(CLPT) ClearPoint Neuro, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CLPT) ClearPoint Neuro, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This ClearPoint Neuro, Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
ClearPoint Neuro Navigation System
ClearPoint Neuro Navigation System is the clearest Star in ClearPoint Neuro, Inc.'s BCG Matrix: it is the core platform for MRI-guided, minimally invasive brain surgery, used inside the MRI suite for precise targeting and placement. It drives the company's growth story because it sits at the center of recurring procedural use and expanding clinical adoption.
As the main growth engine, it benefits from a high-value neuro navigation market where accuracy and real-time imaging matter most. Its strength is simple: it helps surgeons place therapies more precisely, and that keeps it central to ClearPoint Neuro, Inc.'s long-term revenue mix.
Deep Brain Stimulation electrode placement
ClearPoint Neuro’s MRI-guided platform supports deep brain stimulation electrode placement with sub-millimeter targeting, which is critical for functional neurosurgery. DBS is still a core use case because it treats Parkinson’s disease, essential tremor, and dystonia, and the addressable patient pool keeps growing as diagnosis and referral rates rise. That supports premium adoption in a niche with durable clinical value.
Brain biopsy needle placement
ClearPoint Neuro, Inc.'s brain biopsy needle placement supports targeting for intracranial lesions, and MRI guidance helps improve precision in a high-value procedure. This fits a growth-led Star profile because it sits in a specialized, clinically important niche where accuracy drives adoption and reimbursement value. The category benefits from rising demand for image-guided neurosurgery, even as ClearPoint Neuro continues to scale its broader platform.
Intracranial drug delivery
ClearPoint Neuro’s intracranial drug delivery supports controlled infusion directly into the brain, so it sits in a high-innovation niche with meaningful clinical upside. The company has said this platform is built for precision placement, and the market is still early, which fits a Star profile in the BCG Matrix. Adoption is building, but the use case is specialized and could expand as more neurosurgical programs adopt it.
- High innovation, early adoption
- Direct brain delivery, precision focused
- Star profile if growth keeps building
Laser catheter guidance
Laser catheter guidance is a niche "Star" for ClearPoint Neuro because it fits minimally invasive brain procedures and can support higher-use workflows in neuro-oncology and epilepsy. The addressable need is large: epilepsy affects about 50 million people worldwide, and brain cancers remain a major surgical target, so guided laser therapy has real runway if adoption keeps rising.
- Fits minimally invasive brain therapy
- Supports neuro-oncology and epilepsy use
- Taps large, unmet clinical demand
- High growth, likely early-stage scale
ClearPoint Neuro’s MRI-Guided Star Growth Engine
ClearPoint Neuro, Inc.'s Stars are its MRI-guided brain navigation and therapy tools, led by the ClearPoint Neuro Navigation System. These products fit a Star role because they combine high growth with strong clinical need in DBS, biopsy, and intracranial drug delivery.
Epilepsy affects about 50 million people worldwide, so laser-guided and minimally invasive brain procedures still have room to scale. The same is true for precise MRI-guided targeting, which keeps adoption tied to real surgical demand.
| Star | Why it fits |
|---|---|
| ClearPoint Neuro Navigation System | Core growth platform |
| DBS and biopsy guidance | Precision drives adoption |
| Intracranial drug delivery | Early but high-upside use |
What is included in the product
Detailed Word Document
ClearPoint Neuro BCG Matrix maps its portfolio across Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
One-page ClearPoint Neuro, Inc. BCG Matrix for quick quadrant insights and easier strategic decisions
Reference Sources
Provides a traceable source trail for ClearPoint Neuro, Inc., strengthening credibility and making decisions easier to defend.
Cash Cows
Disposable procedure kits
Disposable procedure kits are ClearPoint Neuro, Inc.'s classic Cash Cow: they recur with every case, so each installed system can keep generating follow-on sales. That repeat use means steadier revenue and less sales friction than capital equipment, which fits a mature, high-margin BCG layer. In practice, the installed base keeps pulling kit demand case after case.
Installed U.S. system base
ClearPoint Neuro’s U.S. installed base is a Cash Cow because the company is still mainly U.S.-focused, so each new system can feed recurring service and support revenue after the sale. Mature installed accounts are cheaper to keep than to win, which supports higher-margin repeat revenue. That makes the base a stable source of cash even if new placements slow.
Service and training contracts
ClearPoint Neuro, Inc. uses service and training contracts as a cash cow because its MRI-suite workflow needs clinical support, onboarding, and repeat training after adoption. In the latest reported year, ClearPoint Neuro, Inc. generated about $35 million of revenue, and these post-sale services help turn installed systems into recurring cash. Once hospitals are trained, support demand stays steady, so the revenue is sticky and low cost to defend.
Procedure accessories
Procedure accessories are a cash-cow line for ClearPoint Neuro, Inc.: DBS, biopsy, and infusion cases need repeat-purchase consumables, so revenue tracks procedure volume more than platform growth. The company’s latest filings still show this stream is driven by installed-site utilization, not one-time system sales.
- Repeat buys
- Linked to DBS, biopsy, infusion
- Lower growth, steady volume
- Value rises with installed sites
Navigation software upkeep
Navigation software upkeep fits ClearPoint Neuro, Inc.'s Cash Cow profile because software and maintenance fees repeat after adoption, while the clinical workflow is already proven. That makes growth steadier than the launch phase and helps support recurring cash flow, even if the platform is not a high-growth engine.
- Recurring maintenance revenue
- Established clinical use case
- Steadier post-launch growth
- Supports ongoing cash flow
ClearPoint Neuro’s Steady Cash Engine: Repeat Revenue Streams
ClearPoint Neuro, Inc.'s Cash Cows are its repeat-use revenue streams: disposable kits, accessories, service, training, and software upkeep. In the latest reported year, revenue was about $35 million, and these post-sale lines stay tied to the installed base, so they keep cash coming in with less selling effort. That makes them steadier than new-system sales.
| Cash cow line | Why it fits | Data |
|---|---|---|
| Kits, accessories, service | Repeat use | ~$35M revenue |
Preview the Actual Deliverable
ClearPoint Neuro, Inc. Reference Sources
This preview shows the exact ClearPoint Neuro, Inc. BCG Matrix document you’ll receive after purchase. No sample pages, no watermarks, and no demo content—just the full, ready-to-use file. Once purchased, it’s instantly available for download and use. What you see here is what you get.
Dogs
Legacy MRI Interventions branding
Legacy MRI Interventions branding is a legacy asset in ClearPoint Neuro, Inc.'s BCG view, not a growth driver. ClearPoint Neuro rebranded from MRI Interventions, Inc. in February 2020, so the old name no longer supports strategy or sales. The brand adds no current growth role; it mainly reflects pre-2020 history, while ClearPoint Neuro now sells under one identity.
Non-core capital equipment
ClearPoint Neuro, Inc. stays tightly focused on MRI-guided brain surgery tools, so non-core capital equipment fits the Dogs bucket. Low-volume gear outside that niche has weak scale and can soak up cash, inventory, and support time without clear growth. In fiscal 2025, that kind of business is still a small, low-return use of capital versus the core platform.
One-off custom integration work
One-off custom integration work is a Dogs item for ClearPoint Neuro, Inc. because each project is highly tailored, hard to repeat, and slow to scale versus the core platform. That low repeatability makes margins and backlog less predictable, so it is weaker than recurring device and software revenue. It can support customer wins, but it should not drive the BCG view.
Peripheral accessories with low differentiation
ClearPoint Neuro, Inc.’s peripheral accessories fit Dog territory when they lack clear clinical edge and face price pressure. In FY2025, the company’s revenue base was still driven by core navigation and therapy uses, so low-volume accessories likely added little share or growth. That makes them hard to defend when buyers can switch on price.
- Low differentiation = pricing pressure
- Small volume = weak growth impact
- Limited share gain = Dog profile
Small non-U.S. commercialization
ClearPoint Neuro, Inc. remains mainly a U.S. business, so non-U.S. commercialization is still a small part of the mix. That limited reach means overseas sales have not yet become a scale driver, which fits a low-share, low-growth Dogs profile. International expansion may add optionality, but it is not the core demand engine today.
- U.S.-centric revenue base
- Small overseas footprint
- Low share outside the U.S.
- Not a scale market yet
ClearPoint Neuro's Dogs: Legacy Gear, Low-Scale Sales
Dogs in ClearPoint Neuro, Inc.'s BCG view are mostly legacy or low-volume items: the MRI Interventions name was retired in February 2020, and non-core gear still lacks scale. In FY2025, the core business stayed centered on MRI-guided brain surgery, so custom work, accessories, and limited non-U.S. sales added little growth.
| Item | Dog signal |
|---|---|
| Legacy brand | Rebranded Feb 2020 |
| Non-core gear | Low scale |
Question Marks
Cell and gene therapy delivery
Cell and gene therapy delivery is a high-growth adjacency for ClearPoint Neuro, but it is still a small part of the revenue mix. The company’s delivery tools can help enable future therapies, yet current market share is early, so the segment fits a Question Mark in the BCG Matrix. It needs more capital and commercial wins to turn 2025 investment into a future Star.
Boston Scientific partnership programs
ClearPoint Neuro, Inc. lists Boston Scientific as a strategic partner, and that partnership could reach larger hospital and device channels. But demand ownership is not public, so the program’s current share and profit pool are unclear; that makes it a Question Mark.
Boston Scientific is a large-scale partner, with 2025 revenue above $16 billion, so even small pull-through can matter. Still, until ClearPoint shows partner-led program revenue, conversion, and repeat use, the upside is promising but unproven.
Blackrock Neurotech collaboration
Blackrock Neurotech sits in ClearPoint Neuro, Inc.’s question-mark bucket: it is a named partner, and the neurotech market is growing fast, but commercial share is still early.
The upside is real, yet ClearPoint has not shown dominant share or scale from this collaboration in 2025 results, so it needs more adoption before it can move to a star.
For BCG terms, this is a high-potential, low-share play where execution and clinic uptake will decide whether value grows or stalls.
Philips MRI-suite integration
ClearPoint Neuro, Inc.’s Philips MRI-suite integration can widen the guided-therapy workflow, since Philips posted €18.2 billion in 2024 sales and a global MRI base that supports cross-sell. ClearPoint still needs broader hospital adoption to prove it can turn that access into durable market share. Until use scales, this looks more like a Question Mark than a cash generator.
- Expands workflow reach
- Leverages Philips MRI footprint
- Adoption still unproven
UCSF and Johns Hopkins translational programs
ClearPoint Neuro, Inc.'s ties with University of California, San Francisco and Johns Hopkins University fit Question Marks in the BCG Matrix: the science is strong, but near-term revenue is still limited and not separately disclosed. These translational programs can seed future products, but they need clinical proof, regulatory wins, and adoption before they become material.
- High potential, low current revenue
- Early-stage academic-to-commercial path
- Future upside depends on trials
ClearPoint Neuro’s Big Upside, But 2025 Proof Is Still Limited
ClearPoint Neuro’s question marks are early, high-upside adjacencies: cell and gene therapy delivery, partner-led workflows, and academic collaborations. They can scale, but 2025 revenue impact is still small and share is not proven. Boston Scientific topped $16B in 2025 revenue, and Philips posted €18.2B in 2024 sales, so channel reach exists; conversion still needs proof.
| Area | Signal |
|---|---|
| Cell and gene therapy | Low share, high growth |
| Boston Scientific | >$16B 2025 revenue |
| Philips | €18.2B 2024 sales |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.